Expert Interview
A Third View: Discussing Pluvicto for the treatment of metastatic or castrate-resistant prostate cancer in light of its recent FDA approval.
Ticker(s): NVSInstitution: Lake Huron Medical Center
- Radiation oncologist who manages treatment for 12 patients with metastatic or castrate-resistant prostate cancer annualy
- Familiar with the phase 3 data for the Pluvicto trial as treatment for prostate cancer
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
